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Abstract
Background: Differentiated thyroid cancer (DTC) is relatively rare and can metastasize to both the lungs and bones.
The great majority of bone metastases occur in red marrow regions where blood flow is high. Only one patient has
been described with direct DTC metastasis to the subchondral bone of the femoral head.
Case presentation: The patient was a 68-year-old Japanese female who had presented with left hip joint pain at
age 63 years. At age 51 years, she had been diagnosed with DTC and underwent partial excision. X-rays showed
partial femoral head collapse, suggesting osteoarthritis or idiopathic necrosis of the left femoral head. Three years
later, a 131 I whole-body scan showed accumulation in the left femoral head, resulting in a diagnosis of DTC
metastasis to the left femoral head. Bipolar hip arthroplasty was performed. Examination of the excised femoral
head resulted in a final diagnosis of metastasis of follicular thyroid cancer, which was limited histopathologically to
the subchondral bone of the femoral head.
Conclusion: Tumor metastasis to the subchondral bone of the femoral head is exceedingly rare. Overall survival of
patients with bone metastasis is improved by complete resection. Differential diagnosis of patients with a previous
history of DTC who present with femoral head collapse should include bone metastasis of DTC.
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Background
Thyroid cancer is a relatively rare disease, accounting
for approximately 1 % of all malignant neoplasms, about
0.5 % in men and 1.5 % in women [1]. Various types of
thyroid cancer have been identified, including differenti-
ated thyroid cancer (DTC), Hürthle-cell cancer, undiffer-
entiated carcinoma and medullary carcinoma. About
90 % of thyroid cancers are DTC, including both
papillary (70–75 %), and follicular (15–20 %) cancers.
Papillary DTC is characterized by indolence and local-
ized spread, but may metastasize to the lungs and bones.
Follicular cancer is known to preferentially metastasize
to the lungs and bones [2]. Bone metastases have been
reported in 2.3–12.7 % of patients with DTC [3]. Most
bone metastases occur in areas of high blood flow,
including the red marrow regions of the axial skeleton,
including the vertebrae (42–52 %), femur (9–20 %), skull
(2–16 %) and pelvis (5–13 %) [4, 5].
Blood for the femoral head is supplied by branches of
the profunda femoris artery, e.g. the lateral and medial
circumflex femoral arteries. Furthermore, there is little
collateral circulation, resulting in ischemic necrosis.
Bone metastasis were reported difficult to distinguish
from osteonecrosis or arthritis on magnetic resonance
imaging (MRI) and fluorine-18 fluorodeoxyglucose
whole-body positron emission tomography (FDG-PET)
[6]. The most common site of femur metastasis in
various cancers, including thyroid cancer, is the femoral
neck (50 %), Followed by the subtrochanteric (30 %) and
intertrochanteric (20 %) regions [7, 8]. To date, no pa-
tient with breast cancer has shown a single metastasis to
the femoral head alone; rather, patients with femoral
head metastasis had more than five metastasic lesions
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each [9]. Thyroid cancer metastasis to the subchondral
bone of the femoral head is exceedingly rare, with only
one previous patient described [10]. This report de-
scribes a patient with a thyroid cancer metastasis to the
subchondral bone of the femoral head.
Case presentation
The patient was a 68-year-old Japanese female who had
presented with left hip joint pain at age 63 years. At age
51 years, she had been diagnosed with thyroid cancer
and underwent partial excision, with the pathological
diagnosis being a follicular DTC. At age 62 years, she
was diagnosed with cancer in the right kidney, which
was totally excised.
At her first visit for hip pain, physical examination of
the hip and blood tests showed no abnormal findings.
However, X-rays (Fig. 1a) and computed tomography
(CT) (Fig. 1b) showed partial femoral head collapse. On
MRI, the focal lesion of the femoral head had a band-
like shape, with low intensity on T1WI and high inten-
sity on STIR, (Fig. 1c, d). Bone scans showed no
accumulation of radioactivity, except for the femoral
head (Fig. 2). The patient was differentially diagnosed
with osteoarthritis of the hip or idiopathic necrosis of
the femoral head. Because she had slight pain in the hip
joint, she was followed up by X-rays of her hip joint.
Three years after the initial consultation, a bone metas-
tasis was observed in her right rib and was excised. The
excised tumor was diagnosed histopathologically as a
metastasis of follicular thyroid cancer. Subsequently,
X-rays (Fig. 3a) and MRI (Fig. 3b) showed that the lesion
and the area of collapse had expanded, with a 131 I whole-
body scan showing accumulation of radioactivity in the
left femoral head (Fig. 3c). These findings suggested that
the lesion in the femoral head was a metastasis of thyroid
cancer. The patient underwent bipolar hip arthroplasty
(BHA) (Fig. 4a), with the excised femoral head diagnosed
as a metastasis of follicular thyroid cancer. Histopatho-
logic examination showed that the cancer cells were lim-
ited to the subchondral bone of the femoral head (Fig. 4b).
The day after surgery, the patient was able to walk with
full-weight-bearing. At present, 18 months after BHA,
there has been no evidence of additional metastatic lesions
and her Musculoskeletal Tumor Society (MSTS) score
[11] is 100 %.
Conclusions
DTC is one of the most curable cancers [12]. DTCs are
characterized by a slowly progressive course, and have a
10-year survival rate of 80–95 % [2]. However, the
occurrence of distant metastases reduces the overall
10-year survival rate to 40 % [13]. Previous studies have
reported that 25 % of metastases were to the bone, 49 %
to the lung and 15 % to both. Bone metastases have been
reported in 2–13 % of patients with DTC, being sig-
nificantly more frequent in patients with follicular cancer
(7–28 %) than in those with papillary cancer (1.4–7 %)
[13–15]. The patient described here had follicular cancer.
Fig. 1 a X-ray of the hip joint showing left partial femoral head collapse. b CT image showed a lesion in the loaded part of the left femoral head.
c Coronal T1 weighted image (T1WI) on MRI, showing low intensity of the left femoral head lesion. d Coronal short tau inversion recovery (STIR)
on MRI, showing partially high intensity of the femoral head lesion
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Patients with thyroid cancer and bone metastases have a
poor prognosis, with 10-year survival rates ranging from
0–34 % [16]. Complete resection of bone metastases of
DTC has been associated with a significant improvement
in survival [3, 17].
Most bone metastases of DTC occur in regions of
high blood flow, including the vertebrae (42-52 %),
femur (9–20 %), skull (2–16 %) and pelvis (5–13 %)
[4, 5]. Anatomically, bone metastasis to the femoral
head is very rare, with direct involvement of the sub-
chondral region reported in only one previous patient
[10]. Diagnosis is therefore very difficult, with these
lesions appearing similar on imaging modalities to
osteonecrosis and osteoarthrosis.
Bone metastases of thyroid cancer may be accom-
panied by pain, but often are clinically silent, making
them difficult to detect. Imaging modalities, including
whole body bone MRI, CT, bone scan, 131 I whole-body
scan (WBS) and FDG-PET, should be performed in pa-
tients with suspected bone metastases of DTC. Whole
body MRI provides detailed images of both bone and
bone marrow. CT can evaluate the extent of metastatic
lesions and is especially useful for sites that are difficult
to evaluate. If whole body MRI or CT detects a bone
metastasis, a directed MRI or CT scan should be
employed to specifically define the lesion of interest and
aid in the planning of surgery or radiotherapy or the use
of novel modalities to treat destructive osseous metasta-
ses. Bone scans with 99mTc diphosphonate or methylene
diphosphonate (MDP) are most frequently used for
localization and staging. 131 I-WBS is more specific and
sensitive than a bone scan but only for well differen-
tiated thyroid cancer [4]. These scans have low sensi-
tivity in detecting distant metastases from thyroid cancer
and in localizing bone metastases. In contrast post-
treatment 131 I-WBS may be highly sensitive (61–65 %)
Fig. 2 Bone scan showing that the only metastatic lesion was in the femoral head
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in detecting osseous lesions, as in the patient described
here. Because 131 I-WBS can detect some, but not all,
bone metastases, further testing is needed [16]. For
example, FDG-PET shows preferential tracer uptake by
malignant cells with a high turnover rate due to
increased glucose metabolism. FDG-PET is useful in
patients with metastatic poorly differentiated thyroid
cancer, in those with high thyroglobulin levels and in pa-
tients negative on 131 I-WBS [18]. X-rays and CT scans
in the patient described here showed femoral head col-
lapse, whereas MRI showed that the focal lesion of the
femoral head had the shape of a band, with low intensity
on T1WI and high intensity on STIR. Furthermore, bone
scans showed no other metastatic lesions. The diffe-
rential diagnosis included osteoarthritis of the hip and
idiopathic necrosis of the femoral head. Three years
later, a metastasis in the right rib was detected, with 131
I-WBS showing the metastasis to the left femoral head.
Because the overall survival of patients with bone metas-
tasis is improved by complete resection, early diagnosis
and treatment is important. Bone metastasis of DTC
should be considered in the differential diagnosis of
patients with a previous history of DTC and femoral
head collapse.
Fig. 3 a X-ray of the hip joint 3 years after initial consultation, showing that the collapsed area had expanded. b Coronal T1 weighted MR image
showing expanded low intensity of the left femoral head lesion. c 131 I whole-body scan (WBS) showing accumulation of radioactivity in the left
femoral head
Fig. 4 a X-ray, showing the left hip joint after BHA. b Photograph of the vertically divided left femoral head after surgery. DTC was observed in
the subchondral region of femoral head (arrowhead). There was no cartilage discontinuity
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Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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